NCT03691064 - Post-Authorization Long-Term Safety Study of LUTATHERA | Biotech Hunter

Enrollment

1,014

Participants

Timeline

Start Date

November 28, 2018

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions

Neuroendocrine Tumors

Interventions

DRUG

LUTATHERA

Labeled dosing regimen: 7.4 gigaBecquerel (GBq) (200 milliCurie \[mCi\]) every 8 weeks for a total of 4 doses.

Trial Locations (20)

15706

Novartis Investigative site, Santiago de Compostela

28222

Novartis Investigative site, Majadahonda

43210

The Ohio State University Wexner Medical Center, Portland

85006

Banner MD Anderson Cancer Center, Phoenix

97339

Oregon Health & Sciences University Hospital, Portland

98101

Virginia Mason in Seattle, Seattle

Unknown

Novartis Investigative site, Clichy

Novartis Investigative site, Lyon

Novartis Investigative site, Villejuif

Novartis Investigative site, Manchester

3000-075

Novartis Investigative site, Coimbra

B152WB

Novartis Investigative site, Birmingham

CB2 0QC

Novartis Investigative site, Cambridge

G12 OYN

Novartis Investigative site, Glasgow

L7 8XP

Novartis Investigative site, Liverpool

NW32QG

Novartis Investigative site, London

SE1 9RT

Novartis Investigative site, London

SE5 9RS

Novartis Investigative site, London

W6 8RF

Novartis Investigative site, London

S102SJ

Novartis Investigative site, Scheffield